ResearcherLovely Professional UniversityActive in the last 2 years
Md Sadique Hussain
Matched on ORCID iD 0000-0002-3554-1750; OpenAlex author ID A5069889737. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 3
2024: 1 paper · 2025: 2 papers · 2026: 1 paper
Papers 4
- Mesothelin in pancreatic cancer: clinical applications and analytical considerations. Last author DOI 10.1016/j.cca.2025.120686↗
- Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma. First author DOI 10.1186/s40360-025-01020-z↗
- Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fphar.2025.1635449↗
- Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using comp… Co-author DOI 10.1007/s12672-024-01455-6↗
Closest collaborators
The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Prasanna Srinivasan Ramalingam · 3 shared papers, 2024–2025 · strength 0.76
- Paper Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pan… DOI 10.1007/s12672-024-01455-6↗
- Paper Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma. DOI 10.3389/fphar.2025.1635449↗
- Paper Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma. DOI 10.1186/s40360-025-01020-z↗
- Sivakumar Arumugam · 3 shared papers, 2024–2025 · strength 0.76
- Paper Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pan… DOI 10.1007/s12672-024-01455-6↗
- Paper Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma. DOI 10.3389/fphar.2025.1635449↗
- Paper Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma. DOI 10.1186/s40360-025-01020-z↗
- Neeraj Kumar Patel · 1 shared paper, 2026 · strength 0.27
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.